POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine aims to shield transplant patients from Cancer-Causing virus
⭐️ VACCINE ⭐️ TerminatedThis early-stage trial tests a vaccine (OSU-2131) designed to protect against Epstein-Barr virus (EBV) and the cancers it can cause, especially in people waiting for an organ transplant. The study includes healthy volunteers and transplant candidates who carry a specific immune g…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 15, 2026 11:55 UTC
-
Engineered immune cells take on returning blood cancers
Disease control OngoingThis early-stage study tests a new treatment for people with certain B-cell blood cancers (like lymphomas and leukemias) that have come back. The treatment involves taking a patient's own white blood cells, adding a new gene to help them find and kill cancer cells, and giving the…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 03:23 UTC
-
Engineered T-Cells show promise in lymphoma fight
Disease control OngoingThis early-phase study tests a new immune therapy for people with high-risk or returning non-Hodgkin lymphoma. After a stem cell transplant, patients receive specially modified T-cells designed to find and attack cancer cells. The main goal is to check safety and find the best do…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New CMV strategy aims to protect stem cell transplant patients from dangerous infection
Disease control OngoingThis study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC